[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 4th that it will participate in BIOPHARM America, held online in a non-face-to-face format until the 5th, to discuss strategic partnerships with global pharmaceutical companies.
Nahanik, CEO of Canaria Bio, stated, “At this event, we plan to introduce the company’s key pipelines such as ovarian cancer, pancreatic cancer, and metastatic breast cancer, and seek strategic partnerships with global pharmaceutical companies.”
Meanwhile, Oregobomab, the core pipeline for which Canaria Bio is conducting global Phase 3 clinical trials, is a new drug that showed encouraging results in Phase 2 clinical trials targeting newly diagnosed ovarian cancer patients, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months. In addition, another pipeline, Bravarex, a pancreatic cancer treatment, is preparing for Phase 2 clinical trials.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
